The prevalence and severity of MASLD in type 1 diabetes remain unclear. Therefore, we investigated the prevalence and severity of MASLD in type 1 diabetes, and assessed which clinical features are most important in predicting MASLD severity. 453 individuals with type 1 diabetes (41.6±15.0 years, 64% female, BMI 25.4±4.2kg/m2, HbA1c 55.6±12mmol/mol) underwent vibration-controlled transient elastography (VCTE), with a controlled attenuation parameter (CAP) score for steatosis (≥ 280.0dB/m) and a liver stiffness measurement (LMS) for fibrosis (≥ 8.0kPa). A machine-learning Extra-Trees classification model was performed to assess the predictive power of the clinical features associated with type 1 diabetes with respect to steatosis and fibrosis. The prevalence of hepatic steatosis and fibrosis was 9.5% [95% CI 6.8-12.2] and 3.5% [95% CI 1.8-5.2]. Higher LMS was associated with a longer duration of type 1 diabetes (median 30.5 [IQR 18.0-39.3] years vs. 15.0 [IQR 6.0-27.0] years) and individuals were older and had a higher BMI (mean 27.8 ±5.2 vs. 25.3 ±4.1kg/m2), and a higher CAP score (mean 211.4±51.7 dB/m vs. 241.4±75.6 dB/m). The most important predictive features of fibrosis were duration of type 1 diabetes, age, and systolic blood pressure, with a mean± standard deviation (SD) area under the curve of 0.73±0.03. Individuals with type 1 diabetes and high blood pressure, older age, BMI and duration of disease could be considered at high-risk for developing MASLD.